Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Assets Average (2016 - 2025)

Ani Pharmaceuticals' Assets Average history spans 15 years, with the latest figure at $1.4 billion for Q4 2025.

  • For Q4 2025, Assets Average rose 10.76% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, up 10.76%, while the annual FY2025 figure was $1.4 billion, 24.49% up from the prior year.
  • Assets Average for Q4 2025 was $1.4 billion at Ani Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • Across five years, Assets Average topped out at $1.4 billion in Q4 2025 and bottomed at $462.5 million in Q1 2021.
  • The 5-year median for Assets Average is $843.5 million (2023), against an average of $900.1 million.
  • The largest annual shift saw Assets Average fell 1.49% in 2021 before it skyrocketed 63.93% in 2022.
  • A 5-year view of Assets Average shows it stood at $621.0 million in 2021, then increased by 20.7% to $749.6 million in 2022, then increased by 19.69% to $897.2 million in 2023, then skyrocketed by 43.33% to $1.3 billion in 2024, then increased by 10.76% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Assets Average are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.3 billion (Q2 2025).